Life Edit Therapeutics, Inc.

Deal volume was down last year both in M&A and alliances, but valuations rose. Early in 2023, Pfizer Inc. set the tone for a year of moving on from the COVID-19 pandemic by agreeing to pay $43bn for

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Antibiotics Firm Agrees To Go Private F

ElevateBio, LLC launched in 2019 as a cell and gene therapy R&D and manufacturing hub for its subsidiary companies and partners, and with demand for its know-how growing, the firm has raised $410m in

Generation Bio Co. ’s platform technology got a big stamp of approval thanks to a deal with Moderna, Inc. that grants Moderna the option to license Generation Bio’s lipid nanoparticle (LNP) and DNA